InspireMD announces EFS agreement with Jacobs Institute for CGuard EPS in tandem lesion stroke patients

InspireMD, Inc.

Agreement with Jacobs Institute to execute an Early Feasibility Study (EFS) of CGuard EPS for acute stroke with tandem lesions.
EFS to enroll 15 patients across 3 U.S. sites; no FDA-approved stents currently exist for this indication.
CGuard EPS features MicroNet mesh covering for embolic protection, low metal surface area to reduce thrombotic risk.
CEO Marvin Slosman states tandem lesion indication is a critical component of long-term growth strategy.
Dr. Siddiqui notes ~20% of acute strokes are tandem, and stenting in conjunction with thrombectomy may be superior.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.